News | November 08, 2019

One-Year Results of the DISAPEAR Registry Positive for Absorb Stent

The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with chronic limb-threatening ischemia (CLTI) in the DISAPEAR Registry

 Bioresorbable stent Abbott Absorb stent

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with chronic limb-threatening ischemia (CLTI) in the DISAPEAR Registry. This included complex infrapopliteal disease and comorbidities such as diabetes and renal failure, said Steven Kum, M.D., who presented the trial at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

Future prospective controlled studies can further help corroborate the significance of these findings, Kum said.

The Abbott Absorb BVS has demonstrated favorable short- and medium-term results in below-the-knee vessels in patients with CLTI or claudication. The DISAPEAR registry aimed to evaluate the safety and effectiveness of the Absorb BVS in an Asian cohort exclusively with CLTI.

A retrospective analysis was performed in patients with Rutherford class 4 to 6 CLTI with de novo infrapopliteal lesions with angiographic stenosis > 50 percent who were treated with Absorb BVS between August 2012 and June 2017 at Changi General Hospital, Singapore. Assessments included technical success, primary patency (duplex ultrasound peak systolic velocity ratio < 2.0), freedom from clinically driven target lesion revascularization (CD-TLR), amputation-free survival, limb salvage, and wound healing at 6 and 12 months after the index intervention.

Forty-one patients (41 limbs) with 53 lesions were treated with 69 scaffolds during the study period. About 90 percent of the patients had diabetes, 59 percent had ischemic heart disease, 12 percent had dialysis-dependent renal failure, and 93 percent had Rutherford category 5/6 ischemia with tissue loss.

Technical success was achieved in all patients. The mean lesion length was 22.7 ± 17.2 mm. Twenty-four percent of lesions were classified as severely calcified according to the PARC classification. The primary patency rates at 6 and 12 months were 95 percent and 86 percent, respectively. The corresponding rates of freedom from CD-TLR were 98 percent and 93 percent. Freedom from major amputation was 98 percent at both time points and amputation-free survival was 93 percent and 85 percent at 6 months and 1 year after the index procedure. Complete wound healing occurred in 79.5 percent of patients with Rutherford 5 and 6 ischemia by the end of 12 months after the index procedure. There were no deaths within 30 days of the index intervention.

Find information on all the VIVA 2019 Late-breaking Clinical Trials


Related Content

News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
News | Cardiovascular Clinical Studies

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
News | Cardiovascular Clinical Studies

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Cardiovascular Clinical Studies

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
News | Cardiovascular Clinical Studies

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
News | Cardiovascular Clinical Studies

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) ...

Home October 20, 2023
Home
News | Cardiovascular Clinical Studies

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home October 12, 2023
Home
Subscribe Now